Marshall Wace, LLP Rain Therapeutics Inc. Call Options Transaction History

Marshall Wace, LLP

  • $77.3 Billion
  • Q3 2024

Call Options

0 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
No transaction found.

Others Institutions Holding RAIN

# of Institutions
3
Shares Held
122K
Call Options Held
0
Put Options Held
0
View Full List

About Rain Therapeutics Inc.

RAIN Quotes by TradingView
  • Ticker RAIN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 18,837,400
  • Description
  • Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is milademetan, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing milademetan which is in...
More about RAIN
Track This Portfolio

Track Marshall Wace, LLP Portfolio

Follow Marshall Wace, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email